Journal of Arthroplasty
Journal of Arthroplasty
4 years ago

Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even With Prophylactic Anticoagulants

Symptomatic pulmonary embolism (PE), a significant and life-threatening complication following total knee arthroplasty (TKA), has been described as a “never event.” Despite a number of advancements in care, PE continues to occur following TKA. This study evaluates symptomatic PE rates over time in TKA patients enrolled in multicenter randomized clinical trials assessing the efficacy of venous thromboembolism prophylaxis regimens. Methods The MEDLINE and Cochrane Central Register of Controlled Trials were searched to identify clinical trials assessing prophylactic anticoagulation in patients undergoing TKA between January 1995 and December 2016. A random effect model was used to combine PE rates across studies. The pooled proportion of symptomatic PEs was calculated and heterogeneity was quantified with the I2 statistic. A 95% prediction interval was constructed to examine what the expected range in the proportion of symptomatic PEs would be in future studies. Meta-regression was used to explore the effect of time on the rate of symptomatic PEs. Results A total of 18 studies representing 27,073 patients were included in the meta-analysis. The symptomatic PE rate was 0.37% (95% confidence interval, 0.24%-0.52%). There was significant heterogeneity across studies, I2 = 66%. Between 1996 and 2010, the proportion of PEs did not change in the regression analysis. The 95% prediction interval was 0.0002 to 0.0106, indicating that in similar future studies, the true proportion of symptomatic PEs would range from 0.02% to 1.06%. Conclusion Over a 14-year period, the symptomatic PE rate after TKA was relatively constant even when patients received potent anticoagulation. These results suggest that some patients may have a genetic predisposition to develop a PE and more effective risk stratification protocols need to be developed to make sure patients receive appropriate anticoagulation.

Publisher URL: www.sciencedirect.com/science

DOI: S0883540317305703

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.